JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

Search

CareDx Inc

Gesloten

SectorGezondheidszorg

18.81 -8.15

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

18.7

Max

20.48

Belangrijke statistieken

By Trading Economics

Inkomsten

10M

1.7M

Verkoop

13M

100M

K/W

Sectorgemiddelde

15.953

84.243

Winstmarge

1.674

Werknemers

644

EBITDA

11M

6.8M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

-12.75% downside

Dividenden

By Dow Jones

Volgende Winsten

25 feb 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

301M

1.1B

Vorige openingsprijs

26.96

Vorige sluitingsprijs

18.81

Nieuwssentiment

By Acuity

100%

0%

337 / 352 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

CareDx Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 feb 2026, 00:00 UTC

Populaire aandelen

Stocks to Watch: Crown Castle, Qualcomm, Arm, U-Haul

4 feb 2026, 22:55 UTC

Winsten

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook -- Update

4 feb 2026, 21:44 UTC

Winsten

Arm Holdings 3Q Profit Falls Despite Revenue Growth

4 feb 2026, 21:39 UTC

Winsten

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook

5 feb 2026, 00:00 UTC

Winsten

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

5 feb 2026, 00:00 UTC

Winsten

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

4 feb 2026, 23:46 UTC

Marktinformatie

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

4 feb 2026, 23:45 UTC

Winsten

Google to Double Spending as Earnings Beat Wall Street Expectations -- 4th Update

4 feb 2026, 23:32 UTC

Marktinformatie

Gold Rises on Possible Dip-Buying Amid Lingering U.S.-Iran Tensions -- Market Talk

4 feb 2026, 22:59 UTC

Acquisities, Fusies, Overnames

SiTime to Buy Timing Business From Renesas Electronics For $1.5B

4 feb 2026, 22:30 UTC

Winsten

Salesforce Stock Is Battered, and Super Cheap. Hang Tight. -- Barrons.com

4 feb 2026, 22:30 UTC

Winsten

Alphabet's Cloud Is Shining as CapEx Heads Even Higher -- Barrons.com

4 feb 2026, 22:21 UTC

Winsten

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4 feb 2026, 22:17 UTC

Marktinformatie

WiseTech Faces Risks in Both Directions From DSV's Progress -- Market Talk

4 feb 2026, 22:15 UTC

Marktinformatie

Santos Should Lay Out Strategic Plans at Annual Result -- Market Talk

4 feb 2026, 22:00 UTC

Marktinformatie

ESG Roundup: Market Talk

4 feb 2026, 21:53 UTC

Winsten

Google to Double Spending as Earnings Beat Wall Street Expectations -- 3rd Update

4 feb 2026, 21:51 UTC

Winsten

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4 feb 2026, 21:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

4 feb 2026, 21:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Financial Services Roundup: Market Talk

4 feb 2026, 21:50 UTC

Marktinformatie
Winsten

Auto & Transport Roundup: Market Talk

4 feb 2026, 21:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

4 feb 2026, 21:45 UTC

Winsten

Arm Holdings Reported Record Revenue. The Stock is Falling. -- Barrons.com

4 feb 2026, 21:44 UTC

Winsten

Qualcomm Gives Weak Guidance. The CEO Blames Memory Crunch. -- Barrons.com

4 feb 2026, 21:43 UTC

Winsten

Google to Double Spending as Earnings Beat Wall Street Expectations -- 2nd Update

4 feb 2026, 21:41 UTC

Winsten

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4 feb 2026, 21:36 UTC

Marktinformatie

Latest Canada Green Bond Raises C$2 Billion -- Market Talk

4 feb 2026, 21:30 UTC

Winsten

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4 feb 2026, 21:30 UTC

Winsten

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4 feb 2026, 21:30 UTC

Winsten

Beach Energy Interim Dividend 1 Australian Cent/Sjare

Peer Vergelijking

Prijswijziging

CareDx Inc Prognose

Koersdoel

By TipRanks

-12.75% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 18 USD  -12.75%

Hoogste 18 USD

Laagste 18 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor CareDx Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

4 ratings

0

Buy

4

Hold

0

Sell

Technische score

By Trading Central

14.77 / 18.49Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

337 / 352 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat